| Host: |
E. coli |
| Note: |
STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
2019-nCoV Nucleocapsid-N-His protein was developed from e. coli and has a target region of N-His. For use in research applications. |
| Formulation: |
Supplied as a 0.22 Mu m filtered solution in 20mM TRIS, 500mM NaCl, 0.1mM EDTA, 10% Glycerol, pH8.0. Contact us for customized product form or formulation. |
| Immunoreactivity: |
Measured by its binding ability in a functional ELISA. Immobilized Recombinant SARS-CoV-2 Nucleocapsid at 2 Mu g/mL (100 Mu L/well) can bind Anti-Nucleocapsid antibody with a linear range of 0.12-1.64 ng/mL.2. Measured by its binding ability in a fun |
| Immunogen Region: |
Met1-Ala419 |
| Immunogen: |
Recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Ala419) of SARS-COV-2 (2019-nCoV) Nucleocapsid (Accession #QHD43423.2) fused with an 6×His tag at th |
| Background | Recombinant SARS-CoV-2 (2019-nCoV) Nucleocapsid Protein is produced by E. coli expression system. The target protein is expressed with sequence (Met1-Ala419) of SARS-COV-2 (2019-nCoV) Nucleocapsid (Accession #QHD43423.2) fused with an 6×His tag at the N-terminus. |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
